However, previous studies have largely focused on general breast cancer imaging, often neglecting the specific characteristics of HER2 overexpressing breast cancer, a highly heterogeneous subtype with distinct treatment responses and imaging manifestations after NAT. This evidence concerns the gene ERBB2 and breast cancer.